CLDN18 and gastric cancer: Among them, the interim results of the phase I clinical trial of CLDN18.2-targeted CAR-T cells (CT041) in GC showed that CT041 treatment of CLDN18.2-positive GC patients had 57.1% ORR and 75.0% DCR; the 6-month OS rate was 81.2% and the safety was acceptable (117).